Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 7135 |
| PDBID: | 5IP4 |
| Chains: | B_D |
| Organism: | Lama glama, Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 1.81 |
| Reference: | 10.1074/jbc.M116.726547 |
| Antibody | |
| Antibody: | XA4551 Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Neuronal migration protein doublecortin |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Chain: B
Mutation: NULL
| >5IP4_B|Chain A, B|XA4551 NANOBODY AGAINST C-DCX|Lama glama (9844) QVQLQESGGGLVQAGGSLRLSCTASVNIIGGNHWAWYRQAPGQQRDLVASLSRYNANYADSVKGRFTISRDNAKNAAYLQMNSLKPEDTAIYFCALENYYWGQGTQVTVSSHHHHHHEPEA |
Antigen
Chain: D
Mutation: NULL
| >5IP4_D|Chain C[auth D], D[auth E]|Neuronal migration protein doublecortin|Homo sapiens (9606) ARENKDFVRPKLVTIIRSGVKPRKAVRVLLNKKTAHSFEQVLTDITEAIKLETGVVKKLYTLDGKQVTCLHDFFGDDDVFIACGPEKFRYA |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| Chain residues position delta_SASA
: residuesposition B: VAL4 SER27 VAL28 ASN29 ILE30 ILE31 GLY32 GLY33 ASN34 HIS35 ARG55 TYR56 ASN74 ALA75 LEU98 GLU99 TYR101 TYR102 D: VAL258 ARG259 PRO260 LEU262 LYS274 VAL276 ARG277 VAL278 LEU279 LEU280 ASN281 THR284 HIS286 GLN290 VAL291 ASP294 ILE295 GLU297 ALA298 LYS300 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
